5
Participants
Start Date
October 10, 2017
Primary Completion Date
January 27, 2020
Study Completion Date
September 22, 2021
Stereotactic radiotherapy
Treatment will be planned to deliver a total of 18 to 60 Gy to the planning target volume (PTV) in 3 to 5 fractions over 1 to 2 weeks.
Biological: humanized anti-PD-1 monoclonal antibody
Standard of Care - patient will continue to be given the same PD-1 inhibitor they were receiving prior to study registration
Biological: humanized anti-PD-L1 monoclonal antibody
Standard of Care - patient will continue to be given the same PD-L1 inhibitor they were receiving prior to study registration
Virginia Commonwealth University/Massey Cancer Center, Richmond
National Cancer Institute (NCI)
NIH
Virginia Commonwealth University
OTHER